EGFR and melanoma: A. : BMs from NSCLC receiving SRS to selected lesionsB. : BMs from malignant melanoma receiving SRS to selected lesionsC. : BMs from NSCLC receiving SRS to selected lesions + nivolumab or pembrolizumabD. : BMs from malignant melanoma receiving SRS to selected lesions + ipilimumab, nivolumab or pembrolizumabE. : BMs from NSCLC receiving SRS to selected lesions + EGFR inhibitors